Your session is about to expire
← Back to Search
encorafenib for Melanoma (QUAD01 Trial)
QUAD01 Trial Summary
This trial is testing a combination of three or four drugs to see if they are more effective at treating melanoma than two drugs. The three drugs are a BRAF inhibitor, a MEK inhibitor, and a immunotherapy drug. The fourth drug is another immunotherapy drug.
QUAD01 Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2023 Phase 2 trial • 95 Patients • NCT03693170QUAD01 Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
What is the focus of this research?
"The aim of this study is to find the recommended phase II dose (RP2D) of encorafenib + binimetinib +nivolumab + ipilimumab, which will be evaluated over a 12-month period. Secondary objectives include assessing the response rate per RECIST v1.1 criteria (defined as complete response [CR] + partial response [PR]) and the central nervous system clinical benefit rate (CBR) (defined as complete response [CR] + partial response [PR] + stable disease [SD] >6 months). Other measures include adverse events that are possibly,"
How many individuals are being given this treatment as part of the research study?
"Yes, an update on clinicaltrials.gov today shows that the research team is still looking for willing participants. This study was originally posted on May 8th, 2021 and was last updated March 24th, 2022. They are recruiting 84 individuals from a single location."
Encorafenib is often taken as a treatment for what?
"encorafenib can be used to treat patients that have undergone anti-angiogenic therapy in the past. It is also an effective treatment for malignant neoplasms, unresectable melanoma, and squamous cell carcinoma."
Are investigators looking for more participants in this experiment?
"According to the most recent update on clinicaltrials.gov, this clinical trial is still recruiting patients. The posting went up on 5/28/2021 and was edited for accuracy on 3/24/2022."
Are there any other drugs that have been studied in conjunction with encorafenib?
"As of now, 846 different clinical studies are investigating encorafenib with 89 trials in the third phase. The majority of these encorafenib clinical trials originate from Pittsburgh, Pennsylvania; however, 44960 locations total are running encorafenib trials."
Share this study with friends
Copy Link
Messenger